Modalities of use of ceritinib (Zykadia™), a 2nd generation ALK inhibitor, in advanced stage non-small cell lung cancer;Modalités d'utilisation du ceritinib (Zykadia™), inhibiteur de ALK de 2e génération, dans le cancer bronchique non à petites cellules de stade avancé

Bulletin du Cancer

Volumn 102, Issue 12, 2015, Pages 1053-1057

  Giroux Leprieur, Etienne ^a,b   Fallet, Vincent ^c   Wislez, Marie ^d,e  

^a HÔPITAL AMBROISE PARÉ   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c SAINT JOSEPH HOSPITAL   (France)

^d HÔPITAL TENON   (France)

^e SORBONNE UNIVERSITÉ   (France)

Author keywords

ALK rearrangement; Ceritinib; Non small cell lung cancer

Indexed keywords

CERITINIB; CRIZOTINIB; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SULFONE;

ARTICLE; HUMAN; NON SMALL CELL LUNG CANCER; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; MAXIMUM TOLERATED DOSE; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MAXIMUM TOLERATED DOSE; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SULFONES;

EID: 84949570924     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1016/j.bulcan.2015.09.007     Document Type: Review

References (25)

1. F. Barlesi, H. Blons, M. Beau-Faller, and et al. Biomarkers (BM) France: results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts) J Clin Oncol 31 2013 abstr 8000
2. M. Soda, Y.L. Choi, M. Enomoto, and et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 2007 561 566
3. A.T. Shaw, B.Y. Yeap, M. Mino-Kenudson, and et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK J Clin Oncol 27 2009 4247 4253
4. E.L. Kwak, Y.J. Bang, D.R. Camidge, and et al. Anaplastic lymphoma kinase inhibition in non-small cell lung cancer N Engl J Med 363 2010 1693 1703
5. B.J. Solomon, T. Mok, D.W. Kim, and et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer N Engl J Med 371 2014 2167 2177
6. J.K. Won, B. Keam, J. Koh, and et al. Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor Ann Oncol 26 2015 348 354
7. S. Anai, K. Suzuki, K. Ijichi, and et al. A case of crizotinib-resistant lung adenocarcinoma harboring a KRAS mutation and an EML4-ALK fusion gene J Med Cases 5 2014 631 633
8. A. McLeer-Florin, D. Moro-Sibilot, A. Melis, and et al. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study J Thorac Oncol 7 2012 348 354
9. V. Fallet, C. Toper, M. Antoine, and et al. Crizotinib, modalités pratiques d'un traitement personnalisé Bull Cancer 99 2012 787 791
10. R.C. Doebele, A.B. Pilling, D.L. Aisner, and et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer Clin Cancer Res 18 2012 1472 1482
11. J.F. Gainor, A.M. Varghese, S.H. Ou, and et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer Clin Cancer Res 19 2013 4273 4281
12. R. Katayama, A.T. Shaw, T.M. Khan, and et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers Sci Transl Med 4 2012 120ra17
13. T. Sasaki, J. Koivunen, A. Ogino, and et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors Cancer Res 71 2011 6051 6060
14. C.M. Lovly, N.T. McDonald, H. Chen, and et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer Nat Med 20 2014 1027 1034
15. A. Kogita, Y. Togashi, H. Hayashi, and et al. Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition Int J Oncol 45 2014 1430 1436
16. C. Ji, L. Zhang, Y. Cheng, and et al. Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer Cancer Biol Ther 15 2014 570 577
17. T.H. Marsilje, W. Pei, B. Chen, and et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials J Med Chem 56 2013 5675 5690
18. L. Friboulet, N. Li, R. Katayama, and et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer Cancer Discov 4 2014 662 673
19. A.T. Shaw, D.W. Kim, R. Mehra, and et al. Ceritinib in ALK-rearranged non-small-cell lung cancer N Engl J Med 370 2014 1189 1197
20. D.W. Kim, R. Mehra, D.S.W. Tan, and et al. Ceritinib in advanced anaplastic lymphoma kinase (ALK+) non-small cell lung cancer (NSCLC): results of the ASCEND-1 trial J Clin Oncol 32 2014 abstr 8003
21. T. Mok, D. Spigel, E. Felip, and et al. ASCEND-2: a single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ) J Clin Oncol 33 2015 abstr 8059
22. J.F. Gainor, D.S. Tan, T. De Pas, and et al. Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinib Clin Cancer Res 21 2015 2745 2752
23. G. Toyokawa, E. Inamasu, S. Shimamatsu, and et al. Identification of a novel ALK G1123S mutation in a patient with ALK-rearranged non-small-cell lung cancer exhibiting resistance to ceritinib J Thorac Oncol 10 2015 e55 e57
24. S. Park, T.S. Park, C.M. Choi, and et al. Survival benefit of pemetrexed in lung adenocarcinoma patients with anaplastic lymphoma kinase gene rearrangements Clin Lung Cancer 16 2015 e83 e89
25. S.H.I. Ou, J.S. Ahn, L. De Petris, and et al. Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: an open-label, single-arm, global phase 2 study (NP28673) J Clin Oncol 33 2015 abstr 8008